AX-2026-041862

ARA-290 · 2 mg declared · GenScript Biotech Corporation · lot GSP-2605-K3362

PASSPURITY ONLY

Report ID: AX-2026-041862
Compound: ARA-290
Compound class: Tissue-repair and immunomodulatory peptides
Supplier: GSP — GenScript Biotech Corporation
Batch / lot: GSP-2605-K3362
Declared label claim: 2mg
Laboratory: Janoshik Analytical
Assay date: 29 May 2026
Submitted: 21 Jun 2026
Quarter: 2026-Q2
Submitter: p.antonsen
Sample provenance: Buyer-sourced

Section 1

Results

Measured against the index acceptance specification for the tissue-repair and immunomodulatory peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 30 min gradient, 214 nm	99.34	% area	≥ 98.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.66	% area	≤ 2.0	PASS
Largest single impurity	RP-HPLC — [D-Ser]-diastereomer	0.47	% area	≤ 1.00	PASS
Identity	not ordered on this submission	not determined	—	required for VERIFIED status	NOT TESTED
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	3.32	%	≤ 10.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	3.04	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.73	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	1.48	EU/mg	≤ 5.0	PASS
Sterility	membrane filtration, USP <71>, 14 d	No growth at 14 d	—	no growth	PASS
Appearance	visual, diffuse light, black and white background	Off-white lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.17	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 30 min gradient	8.63	min	8.72 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.18	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	83,169	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [D-Ser]-diastereomer	0.98	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 83,169, and skew follows the reported asymmetry factor of 1.18. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.47 % impurity against a 99.34 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	ARA-290 — main peak	8.63	4,828,232	99.34	—
2	[D-Ser]-diastereomer	8.51	22,843	0.47	0.000
3	des-Gln truncate (−128 Da)	8.33	5,346	0.11	-128.059
4	acetyl adduct (+42 Da)	9.03	1,944	0.04	+42.011
5	deamidated (+1 Da)	8.41	1,944	0.04	+0.984
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.90	99.34	divergence +0.45 pp vs batch median
Total impurities (% area)	not stated	0.66
Largest single impurity (% area)	not stated	0.47
Water (%)	1.0	3.32
Counter-ion (%)	not stated	3.04
Peptide content (%w/w)	94.2	not determined
Endotoxin (EU/mg)	1.53	1.48
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Domestic warehouse despatch → submitter (2–8 °C, 24 d) → laboratory (courier, cold pack, 5 d) → assay.
Assay date: 29 May 2026
Submitted to the index: 21 Jun 2026
Laboratory: Janoshik Analytical, Ostrava, Czechia
Method basis: 30 min gradient · high-resolution MS
Verification status: PURITY ONLY

What this report does not establish

That the compound is the compound named. No identity confirmation was ordered on this submission. A purity figure describes chromatographic homogeneity of whatever eluted; it does not name it.
How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 3

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

lambda_21421 Jun 2026

At 214 nm the amide bond dominates the response, so a peptide impurity is seen roughly in proportion to its size. 99.34 % on this detection is the conservative reading; a 280 nm trace would flatter it.

quarter_over_quarter21 Jun 2026

A longitudinal set of retail purchases from one supplier across four quarters is the strongest supplier-level evidence available. Several contributors here are building exactly that.

low_n21 Jun 2026

Strong provenance does not fix small n. One well-sourced record is still one record, and the batch page says how many others exist for GSP-2605-K3362.

Section 7

Related records

Same batch — lot GSP-2605-K3362 n=5

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041863	GSP-2605-K3362	Janoshik	2026-Q2	99.36	3.11	—	Buyer-sourced	0	PASS
AX-2026-041864	GSP-2605-K3362	Nordanalyt	2026-Q2	99.92	3.06	—	Buyer-sourced	0	PASS
AX-2026-041865	GSP-2605-K3362	Kestrel	2026-Q2	99.59	3.47	88.9	Buyer-sourced	1	MARGINAL
AX-2026-041866	GSP-2605-K3362	Janoshik	2026-Q2	99.45	2.95	91.1	Buyer-sourced	0	PASS

Batch rollup and reproducibility assessment →

Cross-sections

Other recent ARA-290 records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2026-041767	ASY	ASY-{CAT}-1521	Janoshik	2026-Q3	99.66	4.42	103.7	Buyer-sourced	PASS
AX-2026-043222	SGN	SGN-2605-X9069	PeptideMeter	2026-Q2	98.32	7.36	—	Buyer-sourced	PASS
AX-2026-041907	SinoPep	SNP-2605-G4075	Janoshik	2026-Q2	99.20	5.75	—	Buyer-sourced	PASS
AX-2026-043227	SGN	SGN-2605-X9069	PeptideMeter	2026-Q2	98.38	7.21	95.6	Buyer-sourced	PASS
AX-2026-041906	SinoPep	SNP-2605-G4075	Medutest	2026-Q2	98.94	5.28	—	Buyer-sourced	PASS
AX-2026-042346	Homopeptide	HOMO-2601-T3123	PeptideMeter	2026-Q2	99.70	3.47	—	Buyer-sourced	PASS
AX-2026-043229	SGN	SGN-2605-X9069	Janoshik	2026-Q2	98.21	7.43	—	Buyer-sourced	PASS
AX-2026-043221	SGN	SGN-2605-X9069	Janoshik	2026-Q2	99.09	7.75	92.1	Supplier-supplied	PASS

Other recent GSP records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041831	Survodutide	GSP-2603-E3156	Kestrel	2026-Q3	99.91	5.50	93.2	Buyer-sourced	0	PASS
AX-2026-041836	Survodutide	GSP-2603-E3156	Janoshik	2026-Q3	98.65	5.34	90.3	Buyer-sourced	0	PASS
AX-2026-041837	Survodutide	GSP-2603-E3156	Janoshik	2026-Q3	98.33	5.37	—	Buyer-sourced	0	PASS
AX-2026-041833	Survodutide	GSP-2603-E3156	Janoshik	2026-Q3	98.08	4.91	99.3	Buyer-sourced	0	PASS
AX-2026-041832	Survodutide	GSP-2603-E3156	VendorInvestigate	2026-Q3	98.01	5.14	99.5	Buyer-sourced	0	PASS
AX-2026-041835	Survodutide	GSP-2603-E3156	Nordanalyt	2026-Q3	98.34	5.74	89.0	Buyer-sourced	1	MARGINAL
AX-2026-041834	Survodutide	GSP-2603-E3156	VendorInvestigate	2026-Q3	97.92	5.95	—	Buyer-sourced	0	PASS
AX-2026-041838	Survodutide	GSP-2603-E3156	PeptideMeter	2026-Q3	98.30	5.01	102.4	Buyer-sourced	0	PASS